Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology

被引:379
作者
Buttgereit, F
da Silva, JAP
Boers, M
Burmester, GR
Cutolo, M
Jacobs, J
Kirwan, J
Köhler, L
van Riel, P
Vischer, T
Bijlsma, JWJ
机构
[1] Humboldt Univ, Charite Univ Hosp, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany
[2] Univ Coimbra, Dept Rheumatol, P-3000 Coimbra, Portugal
[3] Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands
[4] Univ Genoa, Dept Internal Med, Div Rheumatol, Genoa, Italy
[5] Univ Med Ctr, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[6] Univ Bristol, Div Med, Rheumatol Unit, Bristol, Avon, England
[7] Hannover Med Sch, Div Rheumatol, Hannover, Germany
[8] Univ Med Ctr, Dept Rheumatol, Nijmegen, Netherlands
[9] Univ Hosp, Dept Internal Med, Div Rheumatol, Geneva, Switzerland
关键词
D O I
10.1136/ard.61.8.718
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In rheumatology and other medical specialties there is a discrepancy between the widespread use and the imprecise designation of glucocorticoid treatment regimens. Verbal descriptions of glucocorticoid treatment regimens used in various phases of diseases vary between countries and institutions. Given this background, a workshop under the auspices of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials was held to discuss this issue and to seek a consensus on nomenclature for glucocorticoid treatment. This report summarises the panel's discussion and recognises that answers derived from consensus conferences are not definitive. Nevertheless, recommendations on glucocorticoid treatment are presented that (1) reflect current and best knowledge available and (2) take into account current clinical practice. A question-answer rationale presentation style has been chosen to convey the messages, to summarise the meeting in a readable format, and to avoid dogmatism.
引用
收藏
页码:718 / 722
页数:5
相关论文
共 21 条
  • [1] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    Boers, M
    Verhoeven, AC
    Markusse, HM
    vandeLaar, MAFJ
    Westhovens, R
    vanDenderen, JC
    vanZeben, D
    Dijkmans, BAC
    Peeters, AJ
    Jacobs, P
    vandenBrink, HR
    Schouten, HJA
    vanderHeijde, DMFM
    Boonen, A
    vanderLinden, S
    [J]. LANCET, 1997, 350 (9074) : 309 - 318
  • [2] SYSTEMIC LUPUS-ERYTHEMATOSUS - EMERGING CONCEPTS .1. RENAL, NEUROPSYCHIATRIC, CARDIOVASCULAR, PULMONARY, AND HEMATOLOGIC DISEASE
    BOUMPAS, DT
    AUSTIN, HA
    FESSLER, BJ
    BALOW, JE
    KLIPPEL, JH
    LOCKSHIN, MD
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 122 (12) : 940 - 950
  • [3] Buttgereit F, 2000, IMMUNOL TODAY, V21, P192
  • [4] Rapid glucocorticoid effects on immune cells
    Buttgereit, F
    Scheffold, A
    [J]. STEROIDS, 2002, 67 (06) : 529 - 534
  • [5] Buttgereit F, 1998, ARTHRITIS RHEUM, V41, P761, DOI 10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO
  • [6] 2-M
  • [7] Cutolo M, 1999, J RHEUMATOL, V26, P282
  • [8] Da Silva JAP, 2000, RHEUM DIS CLIN N AM, V26, P859
  • [9] Hardman JG, 1998, GOODMAN GILMANS PHAR
  • [10] Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis
    Jacobs, JWG
    Geenen, R
    Evers, AWM
    van Jaarsveld, CHM
    Kraaimaat, FW
    Bijlsma, JWJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (01) : 61 - 64